Trial Profile
A phase I study of HBI-8000 in patients with advanced solid tumors and lymphomas
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Aug 2015
Price :
$35
*
At a glance
- Drugs Tucidinostat (Primary)
- Indications Breast cancer; Non-Hodgkin's lymphoma; Solid tumours
- Focus Adverse reactions
- Sponsors Chipscreen Biosciences; HUYA Bioscience International
- 31 Oct 2008 New trial record.